within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10A_InsulinsAndAnalogues.A10AC04_InsulinLispro;

model InsulinLispro
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 3.333333333333333e-07,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.00023,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>InsulinLispro</td></tr><tr><td>ATC code:</td><td>A10AC04</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.23</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Insulin lispro is a rapid-acting human insulin analog used to improve glycemic control in patients with diabetes mellitus. It acts quickly to lower blood glucose levels and is typically administered immediately before meals. Insulin lispro is approved and widely used in current diabetic management, both for type 1 and type 2 diabetes.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after single subcutaneous injection.</p><h4>References</h4><ol><li><p>de la Peña, A, et al., &amp; Ignaut, DA (2015). Subcutaneous Injection Depth Does Not Affect the Pharmacokinetics or Glucodynamics of Insulin Lispro in Normal Weight or Healthy Obese Subjects. <i>Journal of diabetes science and technology</i> 9(4) 824–830. DOI:<a href=\"https://doi.org/10.1177/1932296815573865\">10.1177/1932296815573865</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25697717/\">https://pubmed.ncbi.nlm.nih.gov/25697717</a></p></li><li><p>Chao, M, et al., &amp; Ning, G (2010). Bioequivalence between two human insulin analogs in Chinese population: Glulisine and Lispro. <i>Endocrine</i> 38(1) 48–52. DOI:<a href=\"https://doi.org/10.1007/s12020-010-9326-4\">10.1007/s12020-010-9326-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20960101/\">https://pubmed.ncbi.nlm.nih.gov/20960101</a></p></li><li><p>Shiramoto, M, et al., &amp; Ohwaki, K (2020). Ultra-Rapid Lispro results in accelerated insulin lispro absorption and faster early insulin action in comparison with Humalog. <i>Journal of diabetes investigation</i> 11(3) 672–680. DOI:<a href=\"https://doi.org/10.1111/jdi.13195\">10.1111/jdi.13195</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31816193/\">https://pubmed.ncbi.nlm.nih.gov/31816193</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10AC04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end InsulinLispro;
